Viewing Study NCT05799820


Ignite Creation Date: 2025-12-25 @ 4:18 AM
Ignite Modification Date: 2025-12-26 @ 3:19 AM
Study NCT ID: NCT05799820
Status: UNKNOWN
Last Update Posted: 2023-05-25
First Post: 2023-03-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Sponsor: Qilu Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module